CORONARY DISEASE
Role of stenting in coronary revascularisation
Anthony H Gershlick
Glenfield Hospital, Leicester, UK

Percutaneous treatment for atheromatous coronary disease has developed rapidly in the last 5–10 years. Some technologies, such as laser therapy, have fallen by the wayside as clinical trials and clinical experience demonstrates lack of efficacy or excess complications. Others devices such as intravascular ultrasound are no longer used routinely. Stent use has grown exponentially, however, initially because operators perceived that angioplasty with adjunctive stenting was safer. Developments allowed the procedure to be increasingly undertaken quickly and safely with short inpatient stay. However, treating patients needs to be evidence based. This article highlights the evidence that underpins the clinical impression that stent deployment is now central to percutaneous treatment of coronary artery disease.

Background
Atheromatous coronary artery disease (CAD) has a major impact on health and on medical economics. There are 150 000 admissions for acute myocardial infarction in the UK annually, and the prevalence of angina has been estimated to be between 1–3% (up to 1.8 million for a population of 60 million). The incidence of new angina varies from 3.6–7.9%. Gandhi has published an annual incidence of 0.44/1000/year in the younger age group (26 000/year) and 2.32/1000/year in patients aged 61–70 years (139 000/year or 2320/million/year). Much of the presentation of CAD is the result of progression, or dynamic change, in the coronary atheromatous plaque. Important treatment aims should be stabilisation of the plaque, restoration of flow, and the alleviation of any flow limitation. Mechanical means to negate the effects of atheromatous obstruction (be they coronary surgery or percutaneous intervention) play an important part in improving the outcome in those patients with CAD.

Percutaneous coronary intervention (PCI) has become an increasingly used and successful treatment option over the last 20 years. It has undergone various evolutionary changes and “came of age” in 2000 with the endorsement of routine stent use by the National Institute for Clinical Excellence.

Why stents?
The development of stenting and its current position in PCI came about to some degree by accident. Until the mid 1990s balloon angioplasty alone was the main method of undertaking PCI. A number of studies had demonstrated its superiority over medical treatment alone, but results varied when it was compared to coronary artery bypass surgery (CABG). The ACME trial compared angioplasty with medical treatment for patients with single vessel disease and exercise induced myocardial ischaemia. At six months 64% of the medically treated group still had angina compared to 46% (p < 0.01) of the angioplasty group who were largely not taking anti-anginal medication. The value of intervention in improving symptoms was further supported by the RITA-2 trial, with a significant improvement in exercise tolerance in those treated with angioplasty. The longer term results versus surgery were, however, less convincing.

The RITA-1 trial data compared outcome in patients with single or multivessel disease considered suitable for angioplasty or coronary surgery who were then randomised to one or other treatment. The results showed that early mortality was similar, but at six months those patients randomised to coronary angioplasty (PTCA) had a higher incidence of angina (32% v 11%), a greater need for repeat coronary angiography (31% v 7% for surgery), and a higher need for revascularisation (38% v 11%) compared to those patients who underwent surgery. This supported previous published observational data on the early natural history of angioplasty, which reported restenosis following PTCA in up to 40% of patients. This recurrence rate did not fall despite multiple drug trials designed to test whether the response of the vessel wall to balloon damage could be attenuated. It had been established that restenosis, if it was going to happen, would occur within the first 4–6 months. The two year follow up data from the RITA trial supported this, when the angina rate for PTCA had not changed (31% v 32% at six months), but it had risen in the surgical group from 11% to 22%.

Despite the possible equalisation of outcome with time, PTCA alone remained an unsatisfactory treatment. Published meta-analyses of other comparative trials indicate that while there is no notable difference in mortality between PTCA and surgery at one and three years, further intervention is required more frequently in the angioplasty patients; in the first year 33.7% of patients initially treated with angioplasty required a further procedure compared to 3.3% of those treated with surgery (p = 0.006) (fig 1). While angina rates were higher early after angioplasty, by three years the incidence of angina was the same. It has been proposed that longer term results may favour non-surgical intervention since there is a 2.5% vein graft attrition rate per year with only 50% of grafts patent at 10 years. Up to 15% of angioplasty procedures are undertaken in patients who have had previous coronary artery bypass grafts. The results of balloon angioplasty alone were still unacceptable, however.
Trials of percutaneous transluminal coronary angioplasty (PTCA) Education in Heart surgical patients. The need for intervention during the first year is much greater than for coronary artery bypass graft (CABG) surgery. When angioplasty alone is used, the need for additional intervention during the first year is much greater than for surgical patients.

Figure 1. Trials of percutaneous transluminal coronary angioplasty (PTCA) versus coronary artery bypass graft (CABG) surgery. When angioplasty alone is used, the need for intervention during the first year is much greater than for surgical patients.

- **Consensus**—Acute closure after balloon angioplasty carries a high complication rate.

**Chronic problems: restenosis following angioplasty**

Initial concepts on recurrence or restenosis after balloon angioplasty centred on the neointimal (smooth muscle cell) response. However, clinical drug trials to limit the impact of smooth muscle cell hyperplasia were generally unsuccessful. Concepts evolved to include the importance of the acute luminal diameter gain, recoil, and the impact of negative remodelling (whereby the restenosing artery gets smaller rather than bigger to accommodate the intraluminal tissue) (fig 2). It was generally felt that such mechanical issues were more important than the impact of tissue in-growth. This meant that stent deployment could have an impact on recurrence since it would deal with three of the four factors thought to be important.

The larger the lumen that can be achieved and maintained after PCI, the less impact any restenotic tissue might have. Additionally 60% or so of the loss of lumen is caused by elastic recoil and negative remodelling. Quantitative angiographic data from a number of trials clearly showed that stents produced a significantly greater acute luminal gain, and prevented recoil. Although tissue response to stenting is exacerbated it has less impact since the arterial lumen is larger. Trial data indicate that the difference in final acute minimal luminal diameter can be increased from about 1.7 mm with angioplasty to about 2.7 mm (158%) with stents.

- **Consensus**—Evolving concepts on restenosis suggest a mechanical solution is likely to reduce recurrence rates.

**Is the use of stents justified?: clinical trials**

**Stenting versus angioplasty alone**

Two major trials were designed to assess the medium term angiographic and clinical outcome following de novo (primary) stenting. Angioplasty in these trials was the preliminary procedure to stent delivery but could be used to optimise the post-stent lumen. The two trials (BENESTENT I and STRESS) have clearly shown that stenting in native vessels reduces the incidence of recurrence. In terms of reduction in restenosis rates, the results were remarkably similar in both trials. In the BENESTENT study, the primary clinical end points of myocardial infarction, need for
CABG or re-PTCA, and stroke had a relative risk of 0.68 (95% confidence interval 0.5 to 0.92) in those patients randomised to stenting compared to those undergoing PTCA alone \( (p = 0.02) \). The angiographic restenosis rate, measured quantitatively on follow up angio-gram, was 22% for stenting and 32% for PTCA. For the STRESS trial the restenosis rate was 29.1% for stenting versus 42% in the PTCA arm \( (p = 0.011) \).

A number of equivalence studies have now been published comparing newer stents with the stents used in these trials. Any stent which produces a good acute result leads to recurrence rates of between 15–20% compared to historical results of 35% for PTCA. The WEST, MUSIC, and FINESS trials have confirmed even lower restenosis rates. Use of intravascular ultrasound to optimise the best possible result leads to restenosis rates of < 10%, but this cannot be justified in terms of time and costs.

**Effect of stent use on clinical practice**

While appropriately conducted clinical trials have shown a clear benefit of stenting compared to angioplasty, such trials are sometimes criticised for not being “real life” in that there is always some degree of patient selection. The case for stents in reducing the need for subsequent reintervention is supported further by indirect evidence from the British Cardiovascular Intervention Society (BCIS) audit data. From 1992 to 1998 there was an increase in angioplasties from 11 575 to 24 661 (113%) with an increase in case complexity. During the same period there was a reduction in reintervention rates for restenosis (from 11.6% to 5.2%) mirrored by an increase in stent use from 2.7% of all cases to 69%. This suggests that an increase in stenting reduces the clinical need for reintervention (table 1).

**Is there too much stenting?**

It has been suggested that stenting is used uncritically and unnecessarily. A study designed to assess the potential added value of stenting once a good angioplasty result had been obtained has been published. In this trial (involving only 116 patients) if residual stenosis was less than 0.3 mm, patients were randomised to either stent or no stent; 13.5% of patients developed recoil at 30 minutes and crossed over to the stent group. The results showed that there was no difference in restenosis rate, event-free survival, and target lesion revascularisation between the two groups at follow up. There are a number of important issues related to this study. Firstly, interventionists do not generally stent when they achieve a “stent-like” result. There are certain other messages, however. Of 953 angioplasties considered for this trial only 116 (12%) met the criteria for the study, suggesting that achieving a “stent-like” result in everyday practice is difficult. It is unclear from the cost benefit analysis whether the excess number of balloons that are frequently required to achieve a stent-like result have been included. Finally, one of the stents that was used predominantly

**Table 1  Coronary stenting: impact on requirement for emergency CABG and the need for reintervention in the UK 1992–98**

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of PCIs</th>
<th>Emergency CABG rate (%)</th>
<th>PCI for restenosis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>11575</td>
<td>2.7</td>
<td>11.6</td>
</tr>
<tr>
<td>1993</td>
<td>12937</td>
<td>5.6</td>
<td>12.3</td>
</tr>
<tr>
<td>1994</td>
<td>14624</td>
<td>13.5</td>
<td>11.4</td>
</tr>
<tr>
<td>1995</td>
<td>17344</td>
<td>27.6</td>
<td>9.6</td>
</tr>
<tr>
<td>1996</td>
<td>20511</td>
<td>45.9</td>
<td>9.4</td>
</tr>
<tr>
<td>1997</td>
<td>22902</td>
<td>60.0</td>
<td>7.4</td>
</tr>
<tr>
<td>1998</td>
<td>24661</td>
<td>69.0</td>
<td>5.2</td>
</tr>
</tbody>
</table>

CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
was the GR II stent, which is a coil stent and as such has been associated with a higher restenosis rates. Certainly for the lesions included, stent restenosis rates would be expected to be lower than that cited in this study.

It is clear that if a “stent-like” result can be achieved with one or two balloons then stenting (which with contemporary units requires only one predilatation balloon) need not be necessary. Such immediate success with angioplasty alone is, however, uncommon and attempts to obtain the +5% to -5% residual stenosis routinely seen after stenting is not without attendant risks of dissection and acute vessel closure, since larger balloons and higher pressure may be needed.

- **Consensus**—Stenting improves outcome compared to balloon angioplasty alone. Achieving a stent-like result with angioplasty alone is difficult.

### Stents versus surgery in 2001

Previous trials of angioplasty versus surgery quoted were in the pre-stent era. Stents should have made an impact, reducing or negating the difference between PCI and coronary surgery. There are a number of randomised studies comparing stenting with surgery for multi-vessel disease.

The one year results of the ARTS trial (n = 1200), which compared stenting (mean (SD) 2.7 (0.2) stents per patient) to surgery (2.8 (1.1) anastomoses per patient) in multi-vessel disease have been published. Ninety three per cent of patients received an arterial graft, and the percentage incidence of patients with unstable angina was similar in each group (37% and 36%, respectively). The average duration of the procedures was 1.5 hours for stenting and 4 hours for surgery. The in-hospital stays were 3.4 days and 11.3 days, respectively.

Treatment according to randomisation was successful in 97% of patients treated with stents and 96% of those treated with surgery. Only 0.5% of stented patients needed urgent bypass grafting and a further 1.7% needed elective surgery. At one year the rates of death, acute myocardial infarction or stroke were low and did not differ between the groups (9.5% for stented patients and 8.8% for surgical patients).

However, the event-free survival was higher in the surgical patients (87.3% vs 73.3%) entirely because of the need for reintervention in the stented patients (fig 3). While eliminating in-stent restenosis is the current research aim for many groups worldwide, even when as in this study it results in a 14% difference in need for reintervention, stenting remains cost effective compared to surgery. In the ARTS study stenting saved 4278 Euro in initial procedure costs compared to surgery, and although part of these savings were lost because of a higher need for revascularisation, the net savings at one year were 2965 Euro.\(^{11}\)

The UK based SOS trial is shortly to be published in full. Comparisons between angioplasty plus stenting and minimally invasive surgery to the left anterior descending artery are underway. Others such as the AMIST study have now had substantial funding approval and are recruiting.

- **Consensus**—In-stent restenosis caused by intimal hyperplasia remains a problem.

### Problems with stenting

One problem with stenting is the residual incidence of restenosis. While this may be <10% for intravascular ultrasound (IVUS) direct selected cases and 15% for trial BENESTENT lesions, even if these were real life the impact on the need for repeat procedures would be high. For the 1.2 million angioplasties carried out worldwide each year at a stent rate of 85%, repeat procedures would be required in 153 000 patients. The situation, however, is worse than this. Certain patient subsets have a higher incidence of in-stent restenosis. Data suggest that the rates are higher for both small vessels stented (up to 43%)\(^{16}\) and for multiple stents (32%).\(^{16}\) Diabetics are a particular at risk group, and pre-stenting surgery was advocated based on the BARI trial data. In-stent restenosis rates of up to 55% have been quoted.\(^{17}\)

### Dealing with in-stent restenosis

In-stent restenosis remains one of the challenges for investigators. There is no doubt that treatment in the form of vascular brachytherapy is available. In-stent restenosis rates are reduced by about 60% and the clinical (target revascularisation) rates by about 50% irrespective of whether this is delivered as a β emitter or a γ emitter.\(^{12–15}\) Two recently published trials (START\(^{14}\) and INHIBIT\(^{17}\)) specifically demonstrated that compared to placebo the use of \(^{90}\)Sr/Y and \(^{192}\)Ir radionucleotide post balloonising to deliver 18 Gy at 2 mm from the source wall reduced the in-stent recurrence from

---

*Figure 3. Residual problems with stenting relate to in-stent restenosis requiring repeat angioplasty (RePTCA) or bypass surgery (CABG). CVA, cerebrovascular accident; AMI, acute myocardial infarction.*
42.2% to 14.2% (p < 0.001) and from 48% to 16% (p < 0.0001), respectively. The incidence of tissue re-growth is greater at the edges of the stent (28.8% and 26%, respectively) which, although less than for placebo (45.2% and 52%, respectively), highlights one of the problems with the use of vascular brachytherapy. Others include the worry about long term outcome and in-stent thrombosis. The main problem, however, is that vascular brachytherapy is secondary treatment, and patients have to have developed in-stent restenosis first. A better approach would be primary prevention.

There is no doubt that it is the aim of all clinical investigators to eliminate or significantly reduce the incidence of in-stent restenosis, if only to reduce further the gap between PCI and surgery (currently around 14% mortality, if only to reduce further the gap between PCI and surgery (currently around 14% mortality). Local delivery of an anti-restenotic drug with the stent has the major advantage of being local and potentially cost effective. Two agents are currently in clinical trial.

Paclitaxel, an extract of the yew tree, has clinical use in ovarian cancer. It has specific properties with regard to microtubules, promoting polymerisation of tubulin. It inhibits the disassembly of microtubules, which thus become very stable and dysfunctional, so inhibiting cell division. We have now been able to coat stents with paclitaxel. In the work undertaken at John Hopkins using the pig coronary stent model, the inhibitory effects on smooth muscle activity appear to be dose related with an inhibitory, but not necessary linear, response at a dose of between 10 µg and 187 µg per stent. This, together with the dose related inhibitory effects on post-traumatic endothelial cell regeneration, have led at this stage to the initiation of a European pilot safety study (ELUTES). The trial completed recruitment in April 2001.

A large European based trial of sirolimus is also almost completed. Sirolimus is a naturally occurring macrolcyclic lactone. It has been used as an immunosuppressive agent in renal and islet grafting and for bone marrow transplantation. It binds to a specific cytosolic protein (immunophilin) found in target cells. This complex then binds to a specific regulatory kinase called the “mammalian target of rapamycin” (mTOR), inhibiting its activation, which in turn through inhibition of cell cycle progression suppresses cytokine stimulated T cell proliferation. However, it has other effects, including inhibition of translation of cdk4/cyclin D and cdk2/cyclin E complexes, that are perhaps of greater potential for inhibiting in-stent restenosis. The RAVEL study will be reporting mid 2001. Early results are exciting.

Paclitaxel is being studied in the QUANUM study, being delivered on a specially designed stent (as opposed to the other studies involving a routine stent).

**Consensus:** Vascular brachytherapy is the treatment of choice for diffuse in-stent restenosis. Trials on the use of drug eluting stents are currently underway.

---

**Stenting in certain patient subgroups**

**Stenting following previous CABG**

Long waiting lists for first time surgery, the success of the procedure, and the lower mortality and morbidity associated with angioplasty compared to re-do operation makes non-surgical intervention an attractive method of treating post-CABG patients (about 15% of all PCI). Restenosis rates after angioplasty to vein grafts are known to be higher than in native vessels, however, although the reasons are unclear. Rates of up to 60% have been reported. In some small observational studies the rate of restenosis following stenting has been shown to be less (range 14–34%). A further observational study by the Palmaz-Schatz study group suggests that the clinical outcome and restenosis rates for stented grafts are comparable to those for angioplasty undertaken on native vessels. In other words, the excess rates associated with angioplasty to vein grafts may be “normalised” by stenting. A recently published study (saphenous vein de novo trial) confirmed a better clinical outcome in that the end points of freedom from death, myocardial infarction, repeated bypass surgery or revascularisation were reached less frequently in stented patients (73% vs 58%, p = 0.03). One further challenge for the treatment of old grafts with stents is the incidence of no reflow, where atherosclerotic debris occludes the distal vessel. A recent trial (SAFER) suggests that the outcome (in terms of enzyme defined myocardial infarction) is better if a distal protection device is used.

**Stents for treating occluded vessels**

There is good evidence that using stents in the setting of balloon angioplasty for chronic total occlusions improves the outcome. This was shown in the SICCO trial which reported that 57% of 119 stented patients were angina-free compared to 24% treated with angioplasty alone (p < 0.001). Angiographic restenosis occurred in 32% of stented patients compared to 74% of the PTCA group (p < 0.001) and reocclusion occurred in 12% and 26%, respectively (p = 0.058). Target lesion revascularisation within 300 days was also less frequent in the stented patients (22% vs 42%, p = 0.025). The TOSCA study confirmed the value of stenting in chronic total occlusions. Stenting produced a 45% reduction in clinically driven target lesion revascularisation at six months (15.4% vs 8.4%, p = 0.03).

**Stents in unstable angina.**

Despite some evidence that lesions in patients with unstable angina are more thrombogenic and are therefore potentially at higher risk, intervention for acute coronary syndromes accounts for 40% of the angioplasty workload. Support for the use of stents in the setting of unstable angina is available in the literature. Marzocchi and colleagues have recently published their experience of stenting in the setting of unstable angina. Of 266 consecutive
Education in Heart

patients stented either electively (24%), for bailout (11%) or for suboptimal angioplasty result (65%), the overall 30 day mortality was 0.3% (one patient with cardiogenic shock), and the incidence of non-fatal myocardial infarction was 2.2% (six patients). At longer term follow up (mean (SD) 17.7 (9.4) months) the cardiac mortality was 0.4%, the myocardial infarction rate was 1.5%, and the target lesion revascularisation rate was 9.3%. Again certain subgroups, such as patients with diabetes or those who had longer stents implanted, adversely influenced the outcome.

Stents and acute myocardial infarction

Thrombolysis remains the mainstay of treatment for acute infarction. Intervention in the form of primary angioplasty has been shown to be better than angioplasty in terms of patency and longer term follow up. However, primary angioplasty has a major drawback. Most patients with acute infarcts present to district general hospitals with no interventional facilities. However, in those that do undergo PCI a number of studies have shown that the use of stents appears to confer significant advantage despite the potentially thrombogenic combination of the stent and disrupted thrombogenic atheromatous plaque. The GRAMI trial randomised 104 patients to either balloon angioplasty alone or to balloon angioplasty followed by stent deployment. While procedural success was equally high in both groups (94.2% vs 98%, respectively), in-hospital adverse events were significantly less in the stented group (3.8% vs 19.2%, p < 0.03), and at late follow up event-free survival was 83% for the stented group versus 65% for the angioplasty group (p < 0.002). Other small observational studies appear to show that restenosis rates in patients stented during acute infarction are no higher than for routine stented patients.

The use of angioplasty with stenting, if considered necessary, as compared to repeat thrombolytic or conservative treatment in patients with failed thrombolysis is being tested in the UK based REACT trial being funded by the British Heart Foundation. A similar trial (MERLIN) is comparing repeat thrombolysis and intervention.

**Adjunctive pharmacological treatment**

The use of adjunctive drug treatment was addressed in a previous article in this series. In summary, the FANASTATIC, STARS, ISAR, and most importantly the CLASSICS study showed that antiplatelet treatment following stenting should include ADP receptor blocking agents (clopidogrel loading dose 300 mg and then 75 mg per day for a month) as well as aspirin.

The use of the glycoprotein IIb/IIIa inhibitors is more controversial. The various trials have assessed the monoclonal antibody abciximab (c-7 E3 Fab, ReoPro) (EPIC, EPILOG, CAPTURE, EPISTENT trials and the synthetic small molecules tirofiban (Aggrastat) (PRISM-PLUS, RESTORE, and eptifibatide (Integrilin) (IMPACT, PURSUIT). There is no doubt that these agents have an impact on trial end points, in particular that of enzyme defined myocardial infarction, in those patients with acute coronary syndromes who are troponin T/I positive (CAPTURE), and are especially valuable in this regard in those going on to PCI (CAPTURE, PRISM-PLUS, PURSUIT). Patients at high risk undergoing intervention undoubtedly benefit irrespective of the agent used (EPIC, EPILOG (few stents used), PRISM-PLUS, PURSUIT). Debate is ongoing concerning the true benefit of these agents in routine PCI, despite it being advocated by the National Institute for Clinical Evidence, and also whether one agent is “better” than any of the others. The EPISTENT study suggested benefit in stable patients, but it is less clear if the placebo group included patients who would have received this agent normally. However, if there is the belief that the glycoprotein IIb/IIIa inhibitors are to be used in “all PCIs” then two recent trials would support the use of abciximab. The recently presented ESPRIT study (epitifibatide) indicated benefit only in patients with acute coronary syndrome of < 2 days’ duration (5.75% v 11.1%, p = 0.013), with no benefit in stable patients (5.4% v 7.2%, NS), and the TARGET study (abciximab v tirofiban) demonstrated superiority of abciximab over tirofiban in all patient groups (6.01% v 7.55%, p = 0.037).

There is still the belief, however, that these agents may not be necessary in the routine treatment of patients and the trial to demonstrate this is still needed. While their benefit in those with acute coronary syndrome going onto PCI has been shown, the situation is complicated by the fact that the recent GUSTO IV ACS trial failed to show a benefit with abciximab in acute coronary syndromes, whereas trials of tirofiban and eptifibatide have.

How a patient presenting with acute coronary syndrome should be treated is unresolved. The evidence suggests that they should be given either tirofiban or eptifibatide (there are unlikely to be any head to head comparisons) but not abciximab, but that if they go on to PCI then abciximab is the preferred agent. There are concerns about both cost and receptor occupancy (and bleeding) if a policy of transferring over from the small synthetic molecules to the antibody is proposed. Most will attempt to triage patients, and transfer and intervene with PCI during the infusion of the small molecule agent (first 72 hours). The debate continues.

**Stenting and areas of contention**

Small vessel disease

Previous trials have suggested high restenosis rates (> 45%) in those patients with small vessel disease. Four recent studies have produced
Summary of trials utilising glycoprotein IIb/IIIa inhibitors in patients requiring percutaneous coronary intervention (PCI)

**Abciximab**
- **EPIC** Most benefit in subgroup considered higher risk (acute coronary syndrome) (predominantly balloon angioplasty)
- **EPILOG** Lower dose heparin during the procedure leads to less bleeding with these agents
- **CAPTURE** The benefits, albeit to a lesser degree, occur before PCI in patients with acute coronary syndrome
- **EPISTENT** The use of these agents improves stenting outcome predominantly through a reduction in enzyme defined acute infarction, but additionally there is some mortality benefit especially in diabetics
- **GUSTO IV ACS** Abciximab has no benefits in patients with acute coronary syndrome

**Eptifibatide**
- **PURSUIT** Predominantly a study of acute coronary syndrome showing a small absolute benefit (14.2% vs 15.7%)
- **IMPACT I and II** Predominantly dosing studies
- **ESPRIT** Patients receiving eptifibatide who have acute coronary syndrome do better when undergoing PCI compared to placebo. No benefit was seen in those with stable angina

**Tirofiban**
- **PRISM-PLUS** Tirofiban of benefit in those presenting with acute coronary syndrome (probability of death/acute myocardial infarction 0.9% vs 2.6%), and especially beneficial in those patients going onto PCI (about a quarter in this study)
- **RESTORE** 98% of patients with acute coronary syndrome went on to PCI in this study and an early benefit was seen but this was lost by six months, although retained if re-analysed according to the EPIOC data
- **TARGET** Incidence end point reached significantly less with abciximab compared with tirofiban

The resolved and unresolved problems of stenting

- Stents have been shown to be beneficial in:
  - acute post-angioplasty vessel closure
  - BENESTENT type lesions (short, simple lesions)
  - PCI in coronary vein grafts
  - chronic total occlusions
  - acute coronary syndromes (unstable angina and acute myocardial infarction)
- Stent use remains problematic in:
  - vessels with reference diameter < 3 mm (restenosis rates >25% compared with approximately 15% BENESTENT lesions)
  - diabetics
  - bifurcation disease
- Stent use is as yet unproven in:
  - left main stem disease
  - preventing restenosis with drug elution

conflicting results. A number of studies have recently been published. The SISA trial (n = 325) showed a trend only towards less adverse outcome with stent (Bestent) versus balloon in vessels < 2.9 mm. This was because the acute gain with stenting (1.37 mm vs 0.91 mm, p = 0.0001) was offset by the greater late loss in the stent group (28.5% vs 18.4%, p = 0.0002). In the setting of small vessels such loss cannot be accommodated so easily. The BESMA trial study (n = 381) on the other hand (also Bestent) showed a restenosis rate of 22.7% in the stent group versus 48.8% in balloon group (p < 0.0001) and a target lesion revascularisation rate of 13% versus 25%, respectively (p = 0.016). ISAR-SMART showed no benefit from stenting (35.7% vs 37.4%, vessel size 2.0–2.8 mm) whereas RAP (Garcia) (vessel size 2.2–2.7 mm) demonstrated a restenosis rate 27% in the stent group versus 37% in the balloon group. The average restenosis rates for these studies in stents deployed in vessels of between 2.2–2.9 mm is 27.5%, double that of BENESTENT lesions. It is clear that physicians will wish not to exclude patients from the potential benefit of stenting based on vessel size. It is likely therefore that it is in this group that drug eluting stents may have most impact since intimal hyperplasia will always have greater impact on the smaller lumen.

Left main stem stenting

It has always been regarded as taboo to undertake PCI on unprotected left main stem disease. However, a number of groups world wide are, through the use of registries, identifying the risk and the patients in whom such intervention could be deemed acceptable. In general early studies such as that by Park suggested excellent results in those at low risk (100% success rate, 17% clinical recurrence at six months and only one death), although Barragan reported three deaths out of 15 high risk patients. Ellis has reported on the ULTIMA registry and the outcome appeared dependent on patient characteristics, ranging from those with stable angina to those deemed inoperable, as well as left ventricular function status. Two hundred and seventy nine consecutive patients who had left main stem PCI at one of 25 sites between 1993 and 1998 were studied. Forty six per cent of these patients were deemed inoperable or at high surgical risk. Thirty eight patients (13.7%) died in hospital, and the rest were followed for a mean of 19 months. The one year incidence was 24.2% for all cause mortality, 20.2% for...
cardiac mortality, 9.8% for myocardial infarction, and 9.4% for CABG. Independent correlates of all cause mortality were: left ventricular ejection fraction (LVEF) < 30%, mitral regurgitation grade 3 or 4, presentation with myocardial infarction and shock, creatinine ≥ 2.0 mg/dl, and severe lesion calcification. For the 32% of patients aged < 65 years, with LVEF > 30% and without shock, the prevalence of these adverse risk factors was low. No periprocedural deaths were observed in this low risk subset, and the one year mortality was only 3.4%. It is likely that PCI for unprotected left main stem disease will be kept for those at high risk from surgery.

**Bifurcation lesions**
The best treatment for bifurcation disease is unresolved. Some would question whether PCI is the treatment of choice, because of technical issues and a high incidence of acute and chronic subsequent events. Stent deployment in both arms of the bifurcation, or the stenting of one and ballooning of the other depending on the presence of disease or the result of intervention, are current topics for debate. While some authors have reported very high restenosis rates, Lefevre et al. reported major adverse cardiac event rates of 17.1–29.2% depending on the learning curve. The use of so-called “kissing” balloons appeared to have a beneficial influence on the outcome. Others have shown that stenting of the side branch may not be essential but choosing which to stent and which to leave is the subject of several proposed studies.

**Direct stenting**
Direct stenting may have significant advantages over routine procedure where there is predilation with a balloon first. There appears little doubt that tissue response to the vessel wall is the result of the damage induced by the balloon inflation (and stent deployment). If this damage could be reduced, less tissue response should occur. Additionally the procedure would be cheaper requiring a balloon-stent unit only. There have been a number of reports outlining the feasibility of such a strategy. Hamon recently published the outcome of 122 "carefully selected" patients. Factors such as calcification and tortuosity need to be taken into account when direct stenting is considered. Procedural success was 96%.

In five cases it was not possible to deliver the stent through the undilated lesion and the stent was retrieved, but in two cases the stent was lost in the peripheral circulation. The authors rightly reported the need for a controlled trial and one UK study (the SLIDE trial) is underway.

**Future directions**
There are three areas of future direction for stents. Firstly, radiation is likely to be incorporated into clinical practice to deal with in-stent restenosis. The second area of development is the use of stents that carry drugs to inhibit the tissue

---

**Trial acronyms**

ACME Angioplasty Compared with Medicine  
AMIST Angioplasty versus Minimally Invasive Surgery Trial  
ARTS Arterial Revascularization Therapy Study  
BARI Bypass Angioplasty Revascularization Investigation  
BENESTENT Belgium-Netherlands Stent Study  
BESMART Bestent in Small Arteries  
CAPTURE Chimeric 7E3 Anti-Platelet in Unstable Angina Refractory to Standard Treatment  
CLASSICS Clopidogrel plus Aspirin Stent International Cooperative Study  
EAST Emory Angioplasty versus Surgery Trial  
ELUTES Evaluation of Taxol Eluting Stent  
EPIC Evaluation of IbIb/IIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications  
EPILOR Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IbIb/IIa receptor blockade trial  
EPISTENT Evaluation of Platelet GP IbIb/IIa Inhibitor for Stenting  
EPIC Evaluation of 7E3 for the Prevention of Ischemic Complications  
ERACI Argentine Randomized Trial Coronary Angioplasty versus Coronary Artery Bypass Surgery in Multivessel Disease  
ESPRIT European Study of Prevention of Reocclusion after Initial Thrombolysis  
FANTASTIC Full Anticoagulation versus Ticlopidine plus Aspirin After Stent Implantation  
FINESS First International New Intravascular Rigid-flex Endovascular Stent Study  
GABI German Angioplasty Bypass Surgery Investigation  
GRAMI GRII stent in Acute Myocardial Infarction  
GUSTO Global Use of Strategies To Open Occluded Coronary Arteries  
IMPACT Integrilin to Manage Platelet Aggregation to Combat Thrombosis Trial  
INHIBIT Inhibit Restenosis Intervention with β-Radiation Trial  
ISAR Intracoronary Stenting and Antithrombotic Regimen  
ISAR-SMART Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries.  
MASS The Medicine, Angioplasty or Surgery Study  
MUSIC Multicenter Ultrasound Stenting in Coronaries  
PRISM-PLUS Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms  
PURSUIT Platelet IbIb/IIa Underpinning the Receptor for Suppression of Unstable Ischemia Trial  
RAVEL Randomized study with sirolimus coated BX Velocity balloon Expandable stent in the treat of patients with de novo native coronary Lesions  
REACT Rescue Angioplasty versus Conservative treatment or repeat Thrombolysis  
RESTORE Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis  
RITA Randomized Intervention Treatment of Angina  
SAFER Saphenous vein graft Angioplasty Free of Emboli Randomized trial  
SICCO Stenting In Chronic Coronary Occlusion  
SISA Stents In Small Arteries  
SLIDE Selected Lesion Indication for Direct Stenting  
SOS Stent Or Surgery  
START Stents and Radiation Therapy Trial  
STARS Stent Anticoagulation Regimen Study  
STRESS Stent Restenosis Study  
TARGET Do Tirofiban And Reopro Give similar Efficacy outcomes Trial  
TOSCA Total Occlusion Study of Canada  
ULTIMA Unprotected Left main Trunk Intervention Multi-center Assessment.  
WEST West European Stent Trial  
WIDEST Wiktor Stent in de Novo Stenosis
responses. The use of such stents is likely to be cost beneficial because of the small amount of drug required in comparison to systemic treatments, provided that the "overall" cost of the stent is not too high and the technology can be applied to longer stents. If shown to be effective in upcoming clinical trials then stents will deal with all four aspects of restenosis; good acute result, recoil, negative remodelling, and in-stent tissue growth.

Finally, there is likely to be an increase in the combined approach to treating multivessel disease, with the interventionist dealing with lesions in the right coronary and circumflex arteries while the surgeon performs a minimally invasive operation on the left anterior descending artery. The rationale for the combined approach is based on the increased difficulty the surgeon has in using arterial conduits to graft the right and circumflex arteries compared to the left anterior descending artery, which may be best treated with a minimally invasive procedure. If this can be done then angioplasty and stenting of the other diseased vessels rather than using the vein as a conduit may be a good option. Clinical trials of such a combined approach are required.

13. Schomig A, Kastrati A, Mudra H, et al. A seminal paper indicating that the better the acute gain the more room there was for the development of any in-stent restenosis, irrespective of device used. Stenting was shown to produce and retain the best acute result.
22. Previous article in the Education in Heart series addressing adjunctive pharmacological treatment in PCI.
Role of stenting in coronary revascularisation

Anthony H Gershlick

*Heart* 2001 86: 104-112
doi: 10.1136/heart.86.1.104

Updated information and services can be found at:
http://heart.bmj.com/content/suppl/2001/06/20/86.1.104.DC1

These include:

**Supplementary material**
Supplementary material can be found at:
http://heart.bmj.com/content/suppl/2001/06/20/86.1.104.DC1

**References**
This article cites 18 articles, 5 of which you can access for free at:
http://heart.bmj.com/content/86/1/104#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Interventional cardiology (2933)
- Clinical diagnostic tests (4779)
- Acute coronary syndromes (2742)
- Percutaneous intervention (964)
- Education in Heart (532)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/